Your download is now in progress and you may close this window

Did you know that with a free Taylor & Francis Online account you can gain access to the following benefits?

Choose new content alerts to be informed about new research of interest to you
Easy remote access to your institution's subscriptions on any device, from any location
Save your searches and schedule alerts to send you new results
Export your search results into a .csv file to support your research

Have an account?
Login now Don't have an account?
Register for free

Login or register to access this feature

Have an account?
Login now Don't have an account?
Register for free

Choose new content alerts to be informed about new research of interest to you
Easy remote access to your institution's subscriptions on any device, from any location
Save your searches and schedule alerts to send you new results
Export your search results into a .csv file to support your research

Search in:

Advanced search

Neuropsychiatric Disease and Treatment Volume 19, 2023 - Issue

Submit an article Journal homepage

Open access

139

Views

CrossRef citations to date

Altmetric

LETTER

Acute Effects of Intravenous Sub-Anesthetic Doses of Ketamine and Intranasal Inhaled Esketamine on Suicidal Ideation: A Systematic Review and Meta-Analysis: Letter in Response [Letter]

Lucian ManuRenaissance School of Medicine at Stony Brook University, Stony Brook, NY, USACorrespondence[email protected]

Pages 1593-1594 | Received 29 Jun 2023, Accepted 04 Jul 2023, Published online: 12 Jul 2023

Cite this article
CrossMark

Full Article
Figures & data
References
Citations
Metrics
Licensing
Reprints & Permissions
View PDF PDF View EPUB EPUB

References

Chen C-C, Zhou N, Hu N, et al. Acute effects of intravenous sub-anesthetic doses of ketamine and intranasal inhaled esketamine on suicidal ideation: a systematic review and meta-analysis. Neuropsychiatr Dis Treat. 2023;19:587–599. doi:10.2147/NDT.S401032
PubMed Web of Science ®Google Scholar
Janssen Pharmaceuticals, Inc. SPRAVATO^® (Esketamine) Nasal Spray, CIII [Prescribing Information]. Titusville, NJ: Janssen Pharmaceuticals, Inc; 2020.
Google Scholar
US Food and Drug Administration. FDA Alerts Health Care Professionals of Potential Risks Associated with Compounded Ketamine Nasal Spray. US Food and Drug Administration Home Page; 2022. Available from: https://www.fda.gov/drugs/human-drug-compounding/fda-alerts-health-care-professionals-potential-risks-associated-compounded-ketamine-nasal-spray. Accessed June 23, 2023.
Google Scholar

Share icon
Back to Top

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.

People also read
Recommended articles
Cited by

To cite this article:

Reference style: APA Chicago Harvard

Citation copied to clipboard

Reference styles above use APA (6th edition), Chicago (16th edition) & Harvard (10th edition)

Download citation

Download a citation file in RIS format that can be imported by citation management software including EndNote, ProCite, RefWorks and Reference Manager.

Choose format: RIS BibTex RefWorks Direct Export

Choose options: Citation Citation & abstract Citation & references